CD8A and neoplasm: Coupling a bacteria Type II secretion protein with the model antigen ovalbumin (OVA), Binder and colleagues show that tumor rejection cannot be fully rescued in late stage B16 melanoma tumors, even with a strong OVA-specific CD8 T cell response (57).